INmune Bio Inc. (INMB) Stock

About INmune Bio Inc.

INmune Bio Inc. is led by CEO David J. Moss, publicly traded since 2019.

INmune Bio Inc. (INMB) stock trades at $1.46 with a market capitalization of $40.52M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.81, reflecting a net loss over the last twelve months, price-to-book of 2.55, price-to-sales of 776.29. Over the past 52 weeks the stock has ranged between $1.09 and $2.60, and currently trades 43.8% below its 52-week high.

On profitability, INmune Bio Inc. generates a return on equity (ROE) of -82.87% (negative, reflecting a net loss), return on capital employed of -96.37%.

INmune Bio Inc. by the numbers, 2016–2025

Between 2016 and 2025 INmune Bio Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit was $-46.0M in 2025.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-17.0M.

Borrowings stand at $1.0M, cash from operations was $-23.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -96.9% over five years, and was -191.7% in the most recent year.

The share price itself has compounded at -40.9% a year over five years, -47.7% over three, -83.4% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

INmune Bio Inc. (INMB) — frequently asked questions